A Randomized, Open-Label, Phase 2 Trial of CMB305 (Sequentially Administered LV305 and G305) and Atezolizumab in Patients with Locally Advanced, Relapsed, or Metastatic Sarcoma Expressing NY-ESO-1
ID Number 16-1338Principal Investigator(s)
Department(s) or Division(s)
Hematology and Medical Oncology
This clinical study is being performed for research purposes. This study will examine the use of the study agents, CMB305 in combination with atezolizumab or atezolizumab alone, in the future treatment of patients with the type of cancer you have. The study will evaluate the safety of the combination of CMB305 and atezolizumab and its ability to stimulate the body's immune system to fight your positive tumor.
Recruiting Patients: Yes